Send to

Choose Destination
Trends Pharmacol Sci. 2005 Nov;26(11):541-4. Epub 2005 Sep 16.

The connections between C75 and obesity drug-target pathways.

Author information

Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.


Obesity and its attendant disorders, such as Type II diabetes, have reached epidemic proportions in the USA, and their prevalence is increasing globally. C75 is a small-molecule inhibitor of fatty acid synthase (FAS) and a stimulator of carnitine palmitoyl 1 activity, which causes profound weight loss in mice. Although C75 is not a compound that is destined for human drug development, it has provided two potential pathways to target in obesity therapy: fatty acid synthesis and fatty acid oxidation. In this article, we discuss the latest data challenging the relationship between fatty acid synthase inhibition and C75-induced anorexia.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center